Table of Content

1. Report Introduction

2. PD-1 and PD-L1 Inhibitors
2.1. PD-1 and PD-L1 Inhibitors Overview
2.2. PD-1 and PD-L1 Inhibitors Types
2.3. PD-1 and PD-L1 Inhibitors Structure
2.4. PD-1 and PD-L1 Inhibitors Mechanism of Action
2.5. PD-1 and PD-L1 Inhibitors Application

3. Competitive Landscape
3.1. Marketed Product Profiles
3.1.1. Keytruda: Merck
3.1.1.1. Product Description
3.1.1.2. Research and Development
3.1.1.2.1. Clinical Studies
3.1.1.3. Other Pipeline Activities
3.1.1.4. Product Development Activities
3.1.1.5. Idhifa Sales

4. PD-1 and PD-L1 Inhibitors - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. PD-1 and PD-L1 Inhibitors Companies Collaborations, Licensing, Acquisition – Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. PD-1 and PD-L1 Inhibitors Collaboration Deals
4.1.2.1. Company–Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Company–University Collaborations (Licensing/Partnering) Analysis
4.1.2.3. PD-1 and PD-L1 Inhibitors Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Stage of Development
5.1.2. Assessment by Product Type (Mono/Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Pipeline Therapeutics
6.1. Comparative Analysis

7. Late-Stage Products (Phase-III)

8. Mid-Stage Products (Phase-II)

9. Early-Stage Products (Phase-I)

10. Preclinical and Discovery Stage Products

11. PD-1 and PD-L1 Inhibitors Emerging Drug Profiles
11.1. BCD-100: Biocad
11.1.1. Product Description
11.1.2. Research and Development
11.1.2.1. Clinical Studies
11.1.3. Product Development Activities
11.1.4. Tabulated Product Summary
11.1.4.1. General Description Table
Many more drugs with detailed profiles provided in the report ?

12. PD-1 and PD-L1 Inhibitors Key Companies

13. PD-1 and PD-L1 Inhibitors Key Products

14. Inactive Products
14.1. Dormant Products
14.1.1. Reason for Dormancy
14.2. Discontinued Products
14.2.1. Reason for Discontinuation

15. PD-1 and PD-L1 Inhibitors - Unmet Needs

16. PD-1 and PD-L1 Inhibitors – Market Drivers and Barriers

17. PD-1 and PD-L1 Inhibitors - Future Perspectives and Conclusion

18. PD-1 and PD-L1 Inhibitors Analyst Views

19. Appendix

20. Report Methodology
20.1. Secondary Research
20.2. Expert Panel Validation



List of Figures


Figure 1 PD-1 and PD-L1 Inhibitors Structure
Figure 2 PD-1 and PD-L1 Inhibitors Mechanism
Figure 3 PD-1 and PD-L1 Inhibitors Types
Figure 4 PD-1 and PD-L1 Inhibitors Clinical Significance
Figure 5 PD-1 and PD-L1 Inhibitors companies collaborations, Licensing, Acquisition – Deal Value Trends
Figure 6 Company–Company Collaborations (Licensing/Partnering) Analysis
Figure 7 PD-1 and PD-L1 Inhibitors Acquisition Analysis
Figure 8 Assessment by Phase of Development
Figure 9 Assessment by Product Type (Mono/Combination)
Figure 10 Assessment by Stage and Product Type
Figure 11 Assessment by Route of Administration
Figure 12 Assessment by Stage and Route of Administration
Figure 13 Assessment by Molecule Type
Figure 14 Assessment by Stage and Molecule Type
Figure 15 Assessment by MOA
Figure 16 Assessment by Stage and MOA
Figure 17 Late-Stage Products (Phase-III)
Figure 18 Mid-Stage Products (Phase-II)
Figure 19 Early-Stage Products (Phase-I)
Figure 20 Preclinical and Discovery Stage Products
Figure 21 Inactive Products
Figure 22 Dormant Products
Figure 23 Discontinued Products
Figure 24 Unmet Needs
Figure 25 Market Drivers and Barriers

 

List of Tables


Table 1 Assessment Summary
Table 2 Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 PD-1 and PD-L1 Inhibitors Acquisition Analysis
Table 4 Assessment by Phase of Development
Table 5 Assessment by Product Type (Mono/Combination)
Table 6 Assessment by Stage and Product Type
Table 7 Assessment by Route of Administration
Table 8 Assessment by Stage and Route of Administration
Table 9 Assessment by Molecule Type
Table 10 Assessment by Stage and Molecule Type
Table 11 Assessment by MOA
Table 12 Assessment by Stage and MOA
Table 13 Assessment by Target
Table 14 Assessment by Stage and Target
Table 15 Late-Stage Products (Phase-III)
Table 16 Mid-Stage Products (Phase-II)
Table 17 Early-Stage Products (Phase-I)
Table 18 Preclinical and Discovery Stage Products
Table 19 Inactive Products
Table 20 Dormant Products
Table 21 Discontinued Products